Posters

Clinical outcomes of calcicol, intrastromal bevacizumab and bevacizumab collyrium in the treatment of alkali ocular surface burn: case report

Poster Details

First Author: G. Mora Botia SPAIN

Co Author(s):    A. Ollero Lorenzo                    

Abstract Details

Purpose:

To evaluate the clinical outcomes of Cacicol ® (ReGeneraTing Agents. RGTA) and improvement of corneal neovascularization with intrastromal and collyrium Bevacizumab (Avastin®) in a case with an alkali ocular surface burn.

Setting:

Complexo Hospitalario Universitario Vigo, Vigo, Spain.

Methods:

A 64 years old male presents a right eye alkali corneal injury grade III. Best corrected visual acuity was 20/60, slit lamp examination showed 40% of inferior limbal ischemia. Conventional treatment during 8 days showed no improvement of the lesion. Calcicol® was started applying one drop every 48 hours with steroids and antibiotic drops for 8 weeks. Extensive neovascularization in the infero nasal cornea was observed at 12 weeks from the time of the injury, administration of Bevacizumab 0.2ml (25mg/ml) was injected in the deep corneal stroma and bevacizumab collyrium 5mg/ml was started topically, 1 drop four times a day.

Results:

After 5 weeks of treatment with Calcicol ®, complete epithelization of a corneal ulcer was observed. Complete regression of corneal neovascularization with one application of instrastromal Bevacizumab and improving with the application of Bevacizumab collyrium, showing a best corrected visual acuity of 20/40.

Conclusions:

Calcicol® therapy belongs to the group of extracellular matrix regenerators (RGTAs). This therapy can be an adequate treatment after alkali corneal injury since it showed good outcomes in the epithelization of the corneal ulcer. Combined with Calcicol ®, intrastromal bevacizumab and bevacizumab collyrium could be a treatment option for corneal neovascularization after alkali ocular surface burn.

Financial Disclosure:

NONE